OBJECTIVE: To evaluate abuse, misuse, and diversion of Xtampza ER, an extended-release (ER) abuse-deterrent formulation (ADF) of oxycodone. METHODS: Abuse, misuse, and diversion of Xtampza ER were assessed using Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System data sources. Xtampza ER was compared with immediate-release (IR) oxycodone, other ADF ER products combined, and non-ADF ER products combined. RESULTS: Xtampza ER prescriptions increased 50-fold during the study period. In contrast, cases from poison centers, substance abuse treatment centers, and diversion were infrequent and did not increase. Adjusted for prescriptions dispensed, poison center exposures were greater for IR oxycodone (rate ratio [RR] = 2.3, P = 0.008), other ADF ER opioids (RR = 5.2, P < 0.001), and non-ADF ER opioids (RR = 2.5, P = 0.004) than for Xtampza ER. In Treatment Center Programs Combined, past-month abuse prevalence for other ADF ER opioids (odds ratio [OR] = 7.4, P < 0.001) and non-ADF ER opioids (OR = 2.0, P = 0.002) was greater than Xtampza ER; IR oxycodone was not significantly different (OR = 1.2, P = 0.349). In the Drug Diversion Program, rates for IR oxycodone (RR = 3.7, P = 0.003), other ADF ER opioids (RR = 4.2, P = 0.002), and non-ADF ER opioids (RR = 3.4, P = 0.007) were greater than Xtampza ER. Adjustment using morphine equivalents provided similar results, except that IR oxycodone in Treatment Center Programs Combined became higher than Xtampza ER. Nonoral abuse cases involving Xtampza ER were infrequent; Web monitoring data support findings that Xtampza ER is difficult to abuse nonorally. CONCLUSION: Xtampza ER abuse, misuse, and diversion and tampering are low relative to other prescription opioid analgesics. Abuse and diversion did not increase over the study period.
OBJECTIVE: To evaluate abuse, misuse, and diversion of Xtampza ER, an extended-release (ER) abuse-deterrent formulation (ADF) of oxycodone. METHODS: Abuse, misuse, and diversion of Xtampza ER were assessed using Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System data sources. Xtampza ER was compared with immediate-release (IR) oxycodone, other ADF ER products combined, and non-ADF ER products combined. RESULTS: Xtampza ER prescriptions increased 50-fold during the study period. In contrast, cases from poison centers, substance abuse treatment centers, and diversion were infrequent and did not increase. Adjusted for prescriptions dispensed, poison center exposures were greater for IR oxycodone (rate ratio [RR] = 2.3, P = 0.008), other ADF ER opioids (RR = 5.2, P < 0.001), and non-ADF ER opioids (RR = 2.5, P = 0.004) than for Xtampza ER. In Treatment Center Programs Combined, past-month abuse prevalence for other ADF ER opioids (odds ratio [OR] = 7.4, P < 0.001) and non-ADF ER opioids (OR = 2.0, P = 0.002) was greater than Xtampza ER; IR oxycodone was not significantly different (OR = 1.2, P = 0.349). In the Drug Diversion Program, rates for IR oxycodone (RR = 3.7, P = 0.003), other ADF ER opioids (RR = 4.2, P = 0.002), and non-ADF ER opioids (RR = 3.4, P = 0.007) were greater than Xtampza ER. Adjustment using morphine equivalents provided similar results, except that IR oxycodone in Treatment Center Programs Combined became higher than Xtampza ER. Nonoral abuse cases involving Xtampza ER were infrequent; Web monitoring data support findings that Xtampza ER is difficult to abuse nonorally. CONCLUSION: Xtampza ER abuse, misuse, and diversion and tampering are low relative to other prescription opioid analgesics. Abuse and diversion did not increase over the study period.
Authors: Stevan Geoffrey Severtson; Becki Bucher Bartelson; Jonathan M Davis; Alvaro Muñoz; Michael F Schneider; Howard Chilcoat; Paul M Coplan; Hilary Surratt; Richard C Dart Journal: J Pain Date: 2013-06-29 Impact factor: 5.820
Authors: Richard C Dart; Hilary L Surratt; Theodore J Cicero; Mark W Parrino; S Geoff Severtson; Becki Bucher-Bartelson; Jody L Green Journal: N Engl J Med Date: 2015-01-15 Impact factor: 91.245
Authors: Jody L Green; Becki Bucher Bartelson; M Claire Le Lait; Carl L Roland; Elizabeth T Masters; Jack Mardekian; J Elise Bailey; Richard C Dart Journal: Drug Alcohol Depend Date: 2017-03-28 Impact factor: 4.492
Authors: Janetta L Iwanicki; S Geoff Severtson; Zachary Margolin; Nabarun Dasgupta; Jody L Green; Richard C Dart Journal: Am J Public Health Date: 2018-12 Impact factor: 9.308
Authors: Suzanne K Vosburg; S Geoffrey Severtson; Richard C Dart; Theodore J Cicero; Steven P Kurtz; Mark W Parrino; Jody L Green Journal: J Pain Date: 2017-12-07 Impact factor: 5.820
Authors: Liza M Reifler; Danna Droz; J Elise Bailey; Sidney H Schnoll; Reginald Fant; Richard C Dart; Becki Bucher Bartelson Journal: Pain Med Date: 2012-02-02 Impact factor: 3.750
Authors: Nabarun Dasgupta; Clark Freifeld; John S Brownstein; Christopher Mark Menone; Hilary L Surratt; Luke Poppish; Jody L Green; Eric J Lavonas; Richard C Dart Journal: J Med Internet Res Date: 2013-08-16 Impact factor: 5.428
Authors: Oluwadara Olatoke; Vladimir Zah; Filip Stanicic; Djurdja Vukicevic; Platonas Yfantopoulos; Christy Thompson; Michael K DeGeorge; Steven Passik Journal: Clinicoecon Outcomes Res Date: 2022-03-03